Alpine Immune Sciences Inc (NASDAQ:ALPN)
| 7.73 Delayed Data As of Mar 31 |  +0.235 / +3.14%Today’s Change | 4.82 Today|||52-Week Range 9.95 | +5.17% Year-to-Date |
Latest ALPN News | Press Releases
| Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates Mar 23 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 7.50 |
| Today’s open | 7.58 |
| Day’s range | 7.43 - 7.79 |
| Volume | 1,628 |
| Average volume (3 months) | 107,133 |
| Market cap | $354.8M |
Data as of 4:00pm ET, 03/31/2023
Growth & Valuation
| Earnings growth (last year) | +12.55% |
| Earnings growth (this year) | +12.24% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +28.24% |
| P/E ratio | NM |
| Price/Sales | 8.17 |
| Price/Book | 1.90 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| STOKStoke Therapeutics I... | +0.18 | +2.21% |
| CLLKFBICO Group AB | +0.27 | +5.42% |
| RCELAVITA Medical Inc | +0.60 | +4.49% |
| VYGRVoyager Therapeutics... | +0.02 | +0.26% |
Data as of 4:00pm ET, 03/31/2023
Financials
| Next reporting date | May 11, 2023 |
| EPS forecast (this quarter) | -$0.37 |
| Annual revenue (last year) | $30.1M |
| Annual profit (last year) | -$57.8M |
| Net profit margin | -192.13% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Seattle, Washington |
Forecasts
